Compounds for immunotherapy of prostate cancer and methods for their use

• US 6,664,377 B1
• Filed: 10/13/2000
• Issued: 12/16/2003
• Est. Priority Date: 02/25/1997
• Status: Expired due to Term

• Current Assignee: Corixa Corporation (GlaxoSmithKline PLC)
• Original Assignee: Corixa Corporation (GlaxoSmithKline PLC)
• Inventors: Xu, Jiangchun
• Primary Examiner(s): Siew, Jeffrey
• Assistant Examiner(s): KIM, YOUNG J
• Application Number:
  US09/688,489
• Time in Patent Office: 1,159 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 530/300, 530/350, 530/387.1, 536/23.1, 536/24.3, 424/130.1
• US Class Current: 530/387.1
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.

Claims

1. An isolated monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:

108.

2. A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with an antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO;

108;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

3. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of an antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:

108.

4. A cancer diagnostic kit comprising at least one antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:

108 and a detection reagent, wherein the detection reagent comprises a reporter group.